Bufalin Suppresses Colorectal Cancer Liver Metastasis by Inhibiting De Novo Fatty Acid Synthesis via the PI3K/AKT-Mediated SREBP1/FASN Pathway
Molecules · 2025
DOI: 10.3390/molecules30173634 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecules, 2025. Verfasst von Wenwen Pang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Laboratory, Tianjin Union Medical Center, Nankai University, Tianjin 300071, China. Hauptthemen laut MEDLINE: Bufanolides, Proto-Oncogene Proteins c-akt, Sterol Regulatory Element Binding Protein 1, Colorectal Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Tianjin Municipal Health Commission, Tianjin Health Technology Project.
Abstract (Originalsprache)
Background
Colorectal cancer (CRC) is the third most common cancer worldwide, with liver metastasis being the leading cause of mortality. De novo fatty acid synthesis plays a critical role in CRC progression and metastasis. Bufalin, a cardiotonic steroid isolated from toad skin, has demonstrated anticancer activity in multiple preclinical models. However, the mechanisms underlying its suppression of CRC metastasis and modulation of fatty acid synthesis remain to be elucidated.
Methods
The effects of bufalin on CRC cell proliferation, migration, and apoptosis were assessed via colony formation, wound healing, and flow cytometry assays. Transcriptome analysis identified bufalin-affected pathways, with changes in gene and protein expression. FASN protein levels were quantified using ELISA.
Results
Bufalin inhibited proliferation and migration of CRC cells and induced the apoptosis of LoVo and HCT8 cells. Transcriptome analysis highlighted lipid metabolism pathways as potential mediators of bufalin’s anti-metastatic activity. Notably, bufalin reduced the expression of fatty acid synthase (FASN) and suppressed CRC metastasis. In vivo experiments demonstrated that bufalin attenuated CRC progression and liver metastasis by inhibiting de novo fatty acid synthesis through the PI3K/AKT-mediated SREBP1/FASN pathway.
Conclusions
Bufalin inhibits de novo fatty acid synthesis via the PI3K/AKT-mediated SREBP1/FASN pathway, suppressing CRC progression and liver metastasis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Laboratory, Tianjin Union Medical Center, Nankai University, Tianjin 300071, China.
- Tianjin Integrative Traditional Chinese and Western Medicine Oncology Institute, Tianjin 300121, China.
- School of Medicine, Nankai University, Tianjin 300071, China.
- School of Integrative Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China.
- Department of Hematology, Oncology Center, Tianjin Union Medical Center, Nankai University, Tianjin 300071, China.
- State Key Laboratory of Component-Based Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China.
ORCID-Profile: Wenwen Pang, Xiang Li, Bowei Zhang, Chunze Zhang
Förderung
- Tianjin Municipal Health Commission
- Tianjin Health Technology Project
Zitieren
APA
Pang, W., Li, X., Yan, S., Zhang, J., Wu, P., Yu, H., Zhang, B., & Zhang, C. (2025). Bufalin Suppresses Colorectal Cancer Liver Metastasis by Inhibiting De Novo Fatty Acid Synthesis via the PI3K/AKT-Mediated SREBP1/FASN Pathway. Molecules. https://doi.org/10.3390/molecules30173634
Vancouver
Pang W, Li X, Yan S, Zhang J, Wu P, Yu H, et al. Bufalin Suppresses Colorectal Cancer Liver Metastasis by Inhibiting De Novo Fatty Acid Synthesis via the PI3K/AKT-Mediated SREBP1/FASN Pathway. Molecules. 2025. doi:10.3390/molecules30173634
BibTeX
@article{Pang2025,
author = {Pang, Wenwen and Li, Xiang and Yan, Suying and Zhang, Junshi and Wu, Ping and Yu, Haiyang and Zhang, Bowei and Zhang, Chunze},
title = {Bufalin Suppresses Colorectal Cancer Liver Metastasis by Inhibiting De Novo Fatty Acid Synthesis via the PI3K/AKT-Mediated SREBP1/FASN Pathway},
journal = {Molecules},
year = {2025},
doi = {10.3390/molecules30173634}
}
EUVIMED